Screener
Capricor Therapeutics CAPR Operating Income
Operating Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-060382
| REVENUE / TOTAL REVENUE | Three Months Ended March 31, 2026 / — | Three Months Ended March 31, 2025 / — |
|---|---|---|
| Research and development | 27,376,912 | 18,915,572 |
| General and administrative | 9,395,941 | 6,067,376 |
| TOTAL OPERATING EXPENSES | 36,772,853 | 24,982,948 |
| LOSS FROM OPERATIONS | (36,772,853) | (24,982,948) |
| OTHER INCOME (EXPENSE) | ||
| Other income | 8,145 | 12,485 |
| Investment income | 2,904,506 | 729,542 |
| Loss on disposal of fixed assets | (81,143) | (150,673) |
Item 1. Financial Statements.
FAQ
- What is Capricor Therapeutics's operating income?
- Capricor Therapeutics (CAPR) reported operating income of -$36.77M in Q1 2026.
- How has Capricor Therapeutics's operating income changed year-over-year?
- Capricor Therapeutics's operating income decreased by 47.2% year-over-year, from -$24.98M to -$36.77M.
- What is the long-term trend for Capricor Therapeutics's operating income?
- Over 4 years (2021 to 2025), Capricor Therapeutics's operating income has grown at a 50.8% compound annual growth rate (CAGR), from -$20.94M to -$108.14M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Capricor Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude